A piece of bacterial protein called corisin has been found to drive pulmonary fibrillation.
Recently, there have been several recent developments in the field of international medical health that continue to attract the attention of the industry and the public. Researchers at the University of Illinois at Urbana-Champaign and Mie University in Japan found that in a new study, a segment of a bacterial protein called corisin drives the process of pulmonary fibrillation. One of the most important principles in medicine is to understand how the disease evolved, which is critical to finding better treatments.
Our findings have transformed antibacterial corisin from just an attractive mechanism associated with fibromyalgia to a biomechanically defined, bioavailable and causal-supported disease driver, especially as a potential therapeutic focus. While leading the study, Professor Isaac Cann, along with Dr. Esteban Gabazza, Professor of Immunology at Mie University, explored how corisin was transformed into a disease-driven factor during disease outbreaks and, through the exploration of biomechanical-defined, bioavailability- and cause-supported disease-driven factors, evolved antibacterial corisin from just an attractive bacterial membrane-associated mechanism to a biomechanical-defined, bioavailability- and cause-supported disease-driven factor.
The exploration of the mechanism, the development of antibacterial corisin from just an attractive mechanism of biochemically defined, biochemically defined and cause-supported disease-driven factor drivers, the development of antibacterial corisin from just an attractive mechanism of biochemically defined, biochemically defined and cause-supported disease-driven factor drivers, the development of antibacterial corisin from just an attractive mechanism of biochemically defined, biochemically active and cause-supported disease-driven factor drivers, the development of antibacterial corisin from just an attractive mechanism of biochemically related and cause-supported disease drivers. According to Gabazza, a neurobiologist at the National Genome Research Institute and the University of Illinois at Urbana-Champaign, who explores biomechanical-defined mechanisms of bioavailability and causation-supported disease-driving factors, fibrillation is the process by which healthy tissues are gradually damaged or killed in exchange for new scar tissue. It can occur in the lungs, kidneys, liver, heart, skin, and other organs, and it contributes to nearly half of all deaths in developed countries, Gabazza said.
In 2020, the team of Kanney and Gabezza discovered coral worms, a protein found in a natural human gut microbiome that kills lung cells and promotes pulmonary fibrillation. However, questions remain as to how it reaches the lungs and whether it directly drives fibrillation or merely exacerbates it. Although further research has found that coenzymes can reach the body from the stomach through blood circulation, Campo and Gabezza decided to investigate whether coenzymes can also be produced in the lungs through bacterial production in the respiratory tract inhabited by bacteria.
The team analyzed samples of pulmonary blood from patients with pulmonary fibrosis, collected during daily clinical care at a hospital in Japan, and samples collected during exacerbation of acute disease, compared to healthy volunteer control samples, and found the DNA of related bacteria in the pulmonary blood samples of patients with pulmonary fibrosis, the first to find evidence of the presence of lithium-producing bacteria in pulmonary fibrosis. Corsin-free fluid loses its lethal effect when applied to healthy cell culture systems. This confirms the bioavailability of Corsin in patients and its ability to directly damage lung cells.
Specifically, when Corsin-free fluid is applied to normal cell culture systems, it loses its lethal effect and can directly damage the cell membranes of lung cells. It should be noted that the above information is based on international public research, compiled for reference by HealthCop, and does not constitute a clinical recommendation.
